
    
      DARE-C is a prospective open label multi-centre pilot study examining the safety and efficacy
      of response guided triple therapy (PEG-IFN, Ribavirin and Telaprevir) for the treatment of
      early chronic HCV genotype 1 infection in individuals with and without HIV infection.
    
  